Thank you, Justin. Today, I'll begin with an overview of our third quarter financial results. Then I'll discuss portfolio performance before concluding with detail on our balance sheet positioning. CGBD had another strong quarter on the earnings front. Total investment income for the third quarter was $56 million, modestly lower compared to prior quarter due primarily to a lower average portfolio balance and lower weighted average yields. Total expenses of $31 million were flat versus prior quarter, as onetime expenses associated with the CLO reset offset reduced total interest expense for both a lower average outstanding debt balance and lower rates. The result was net investment income for the third quarter of $24 million or $0.47 per share. Importantly, adjusted for the expenses associated with the CLO reset adjusted NII was $25 million or $0.49 per share. Our Board of Directors declared the dividends for the fourth quarter of 2024 at a total level of $0.45 per share. That's comprised of the $0.40 base dividend plus a $0.05 supplemental dividend, which is payable to stockholders of record as of the close of business on December 31. This total dividend reflects our variable supplemental dividend policy of paying out at least 50% of excess earnings, which allows us to be flexible as the portfolio evolves and base rates fluctuate. Our base dividend coverage of 118% for the quarter remains in line with the BDC peer set average. And we've consistently out earned our dividend resulting in $1.40 per share of cumulative still. At the same time, the total dividend level also represents an attractive yield of nearly 11% based on the recent share price. And looking ahead, we remain confident in our ability to meet and exceed our $0.40 base dividend. That said, the combination of expected lower base rates, tighter new issue spreads and portfolio repricing activity. We do expect to see some contraction in earnings in coming quarters relative to the historical highs we've achieved over the last two years. On valuations, our total aggregate realized and unrealized net loss was about $5 million for the quarter. The largest contributor was a decline in value at one of the positions in our MMCF JV. However, we successfully exited that position last month at a price materially higher than our 9/30 valuation. And of note, some of our legacy health care names continue to improve, highlighted by incremental markups on SPS and baseline. In terms of credit performance, we continue to see overall stability in credit quality across the portfolio. And as previewed on last quarter's call, non-accruals decreased to only 0.6% of total investments at fair value as we exited our investment in emergency communications at a price in line with our 6/30 fair value. And we continue to work towards favorable solutions with the other two borrowers currently on non-accrual status. I'll finish by touching on our financing facilities and leverage. It's been a busy last few months as we continue to improve our positioning on the right side of our balance sheet. As mentioned on last quarter's call, in early July, we closed a reset of the 2015-1 CLO, extending the reinvestment period and maturity date by four years and reducing the cost of debt by more than 20 basis points within that vehicle. In September, we successfully received investment-grade ratings from both Moody's and Fitch. And then in October, we issued $300 million of unsecured notes with a 6.75% fixed rate, which we swapped to a floating interest rate of SOFR plus 3.23 beginning in August 2025. This transaction further diversifies our financing sources and we'll repay the 2020 for unsecured notes that mature in December while providing additional capital to fund new investment opportunities. At quarter end, statutory leverage is about 1.05 times and net financial leverage was about 0.9 times. With leverage at the low end of our target range of 0.9 to 1.25 times, we have capacity to deploy capital into attractive opportunities in accelerating deal environment. With that, I'll turn the call back over to Justin.